Alto Pharmacy IPO

Alto Pharmacy is a digital pharmacy focused on delivering prescriptions to patients without delivery fees. As with physical pharmacies, patients are able to chat directly with Alto pharmacists to ask questions about their care across general health, sexual health, heart health, fertility, and more. Alto Pharmacy was founded in 2015 by Jamie Karraker, Mattieu Gamache-Asselin, and Vladimir Blumen and is headquartered in San Francisco, CA.

Register for Details

For more details on financing and valuation for Alto Pharmacy, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Alto Pharmacy

To invest in Alto Pharmacy pre-IPO

Can you invest in Alto Pharmacy pre-IPO?

Alto Pharmacy is a privately held company and is not publicly traded, therefore investing in Alto Pharmacy pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Alto Pharmacy before it goes public?

You can seek to sell your shares in Alto Pharmacy while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Alto Pharmacy shares?

To determine the value of your Alto Pharmacy shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Alto Pharmacy shares. You can also learn more about how to sell your private shares before getting started.

Is Alto Pharmacy a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Alto Pharmacy potential IPO

Will Alto Pharmacy go IPO?

Alto Pharmacy has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Alto Pharmacy’s IPO price?

The Alto Pharmacy IPO price does not exist at this time, as Alto Pharmacy is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Alto Pharmacy register for Forge Markets, today.

When was Alto Pharmacy founded?

Alto Pharmacy was founded in 2015.

What is Alto Pharmacy funding to date?

Alto Pharmacy has raised $670.55MM to date.

Who are Alto Pharmacy’s major investors?

Olive Tree Capital
Craig Sherman
Gaingels
Jackson Square Ventures
Daniel Kan
Justin Kan
Flight Ventures
10x Capital
Zola Capital
Soma Capital
What If Ventures
Greenoaks Capital
Undisclosed Investors
Hack Vc
Rahul Mehta
Dst Global
Zola Global
Softbank

Alto Pharmacy Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
09/25/2023 Series EEE-1 $2.58MM $xx.xx $799.9MM What If Ventures
Price per Share
$xx.xx
Shares Outstanding
151,690
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
What If Ventures
09/25/2023 Series CCC-4 $15.69MM $xx.xx $799.9MM What If Ventures
Price per Share
$xx.xx
Shares Outstanding
2,525,760
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
What If Ventures
09/25/2023 Series FF $101.74MM $xx.xx $799.9MM What If Ventures
Price per Share
$xx.xx
Shares Outstanding
16,560,717
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
What If Ventures
01/27/2022 Series EEE $200MM $xx.xx $1.51B Softbank
Price per Share
$xx.xx
Shares Outstanding
12,936,611
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Softbank
02/04/2020 Series DDD $246.4MM $xx.xx $751.58MM Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Softbank, Zola Global
Price per Share
$xx.xx
Shares Outstanding
25,130,023
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Softbank, Zola Global
06/19/2019 Series CCC $30MM $xx.xx $261.15MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,830,751
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
12/05/2018 Series CCC-2 $9.38MM $xx.xx $164.84MM Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
Price per Share
$xx.xx
Shares Outstanding
2,316,805
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
12/05/2018 Series CCC-1 $41.03MM $xx.xx $164.84MM Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
Price per Share
$xx.xx
Shares Outstanding
8,616,165
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
06/12/2017 Series BBB $17.15MM $xx.xx $55.98MM Craig Sherman, Daniel Kan, Greenoaks Capital, Jackson Square Ventures, Justin Kan, Rahul Mehta
Price per Share
$xx.xx
Shares Outstanding
5,902,610
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Craig Sherman, Daniel Kan, Greenoaks Capital, Jackson Square Ventures, Justin Kan, Rahul Mehta
06/10/2016 Series AAA-1 $649,991.76 $xx.xx $17.25MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
774,722
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
06/10/2016 Series AAA $5.95MM $xx.xx $17.25MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,879,912
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 13, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.